Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Back to the forum  2018-06-20 11:24 CEST (UTC+2h)

TRR / RTT Design [RSABE / ABEL]

posted by Helmut Homepage - Vienna, Austria, 2017-05-09 13:06  - Posting: # 17333
Views: 2,610

Hi Yura,

» What if the design of the TRR / RTT obtained by Cmax
» CI T-R = 0.88-1.21;
» CV T-R =48%;
» expansion [0.71-1.40] CV R-R=47%;

Fulfills all requirements for ABEL: CVwR >30%, CI within expanded limits, and PE within 0.8000–1.2500.
Following the ‘logic’ of the EMA’s Q&A document at least 12 subjects should have finished the sequence TRR in order to get a ‘reliable’ estimate of CVwR. I guess that the sample size was 34, right?
If an assessor does not accept this design (not mentioned in the Q&A…) the study demonstrated even ABE.

» GMR T-T=0.708 not belong [0.80; 1.25];
» CI T-T = 0.47-1.06;
» CV T-T =77%.
» Is it possible to draw a conclusion about bioequivalence?

Yes. By definition BE is the (desired) outcome of a comparison of T with R.
The results of T vs. T are interesting but not relevant. BTW, how did you calculate the GMR and the CI? IMHO, if you use only the data of the sequence RTT (as for CVwT) you can evaluate it only as a paired design (e.g., arbitrarily comparing data of the second administration to the first). Such an evaluation assumes no period effects – which might be false.

Cheers,
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. ☼
Science Quotes

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,396 posts in 3,909 threads, 1,175 registered users;
online 37 (2 registered, 35 guests [including 20 identified bots]).

The analysis of variance is not a mathematical theorem,
but rather a convenient method of arranging the arithmetic.    R.A. Fisher

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed